ArticleThe oncologist2025

Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis.

Daniel H Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.